Sustained virological response (SVR) after 48 weeks was 21%, 66%, and 59% for groups 1, 2, and 3, respectively.[ 12 ] Adding boceprevir to the conventional treatment showed highly significant improvement, more ever it also showed favorable response for patients not responding to the treatment with combination of pegylated interferon and ribavarin.[ 12 ] RESISTANCE As with other drugs, boceprevir also showed resistance during Phase III trials.
1
—
—